Work

PT2.12.03 Zongertinib in Patients With Previously Treated HER2-Mutant NSCLC and Brain Metastases at Baseline: Beamion LUNG-1

Year: 2025

Type: article

Source: Journal of Thoracic Oncology

DOI: 10.1016/j.jtho.2025.09.1159

Authors: G. Ruiter, E.F. Smit, R.A. Soo, N. Girard, D. Planchard, M-J. Ahn, E. Nadal, Y-L. Wu, J. Zugazagoitia, N. Yamamoto, B.C. Cho, C. Kim, J. Park, K. Yoh, B. Sadrolhefazi, K. Fernamberg, L. Schroeter, J.V. Heymach

Institutions: The Netherlands Cancer Institute, Leiden University Medical Center, National University Cancer Institute, Singapore, Université de Versailles Saint-Quentin-en-Yvelines, Institut Curie, Université Paris-Saclay, Institut Gustave Roussy, Samsung Medical Center, Sungkyunkwan University, Institut d'Investigació Biomédica de Bellvitge, Institut Català d'Oncologia, Guangdong Academy of Medical Sciences, Guangdong Provincial People's Hospital, Southern Medical University, Hospital Universitario 12 De Octubre, National Cancer Center Hospital, Yonsei University, Yonsei University Health System, Yonsei Cancer Hospital, Georgetown University, Georgetown Lombardi Comprehensive Cancer Center, Macquarie University, National Cancer Center Hospital East, Boehringer Ingelheim (United States), Boehringer Ingelheim (Germany), The University of Texas MD Anderson Cancer Center

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W4415520726

FWCI: 3.456

Cites:

Cited by: 6

Related to: